New Key Statistics Module, Z-Score and F-Score
NYSE:RVTY Key Ratios
| Market Cap $ M | 13,732.94 |
| Enterprise Value $ M | 16,051.51 |
| P/E(ttm) | 58.60 |
| PE Ratio without NRI | 23.00 |
| Forward PE Ratio | 20.89 |
| Price/Book | 1.90 |
| Price/Sales | 4.79 |
| Price/Free Cash Flow | 24.91 |
| Price/Owner Earnings | 27.73 |
| Payout Ratio % | 0.05 |
| Revenue (TTM) $ M | 2,911.00 |
| EPS (TTM) $ | 2.10 |
| Beneish M-Score | -2.57 |
| 10-y EBITDA Growth Rate % | 9.60 |
| 5-y EBITDA Growth Rate % | -11.80 |
| y-y EBITDA Growth Rate % | -0.20 |
| EV-to-EBIT | 49.16 |
| EV-to-EBITDA | 21.73 |
| PEG | -- |
| Shares Outstanding M | 111.59 |
| Net Margin (%) | 8.16 |
| Operating Margin % | 12.27 |
| Pre-tax Margin (%) | 8.96 |
| Quick Ratio | 1.50 |
| Current Ratio | 1.80 |
| ROA % (ttm) | 1.96 |
| ROE % (ttm) | 3.25 |
| ROIC % (ttm) | 3.08 |
| Dividend Yield % | 0.23 |
| Altman Z-Score | 2.83 |
RVTY Number of Guru Trades
RVTY Volume of Guru Trades
Gurus Latest Trades with NYSE:RVTY
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
NYSE:RVTY is held by these investors
Total 2
Revvity Inc Insider Transactions
No Available Data
Guru Commentaries on NYSE:RVTY
EdgePoint Global
Bullish
2025 Q1
What the manager wrote
Revvity Inc. is a global life sciences company that has shifted its innovation focus to faster growing areas such as cell and gene therapy, proteins, genomics, and biologics. This strategic pivot positions Revvity to capitalize on emerging trends in the life sciences sector, enhancing its growth potential. As a recent spinoff of PerkinElmer Inc., Revvity is well-placed to leverage its legacy while expanding its research solutions to a broad client base, making it a compelling investment opportunity.
News about NYSE:RVTY
Total 0- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers